Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline.
Journal
JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
entrez:
29
6
2021
pubmed:
30
6
2021
medline:
6
8
2021
Statut:
ppublish
Résumé
To provide expert guidance to clinicians and policymakers in three resource-constrained settings on diagnosis and staging of adult women with ovarian masses and treatment of patients with epithelial ovarian (including fallopian tube and primary peritoneal) cancer. A multidisciplinary, multinational ASCO Expert Panel reviewed existing guidelines, conducted a modified ADAPTE process, and conducted a formal consensus process with additional experts. Existing sets of guidelines from eight guideline developers were found and reviewed for resource-constrained settings; adapted recommendations from nine guidelines form the evidence base, informing two rounds of formal consensus; and all recommendations received ≥ 75% agreement. Evaluation of adult symptomatic women in all settings includes symptom assessment, family history, and ultrasound and cancer antigen 125 serum tumor marker levels where feasible. In limited and enhanced settings, additional imaging may be requested. Diagnosis, staging, and/or treatment involves surgery. Presurgical workup of every suspected ovarian cancer requires a metastatic workup. Only trained clinicians with logistical support should perform surgical staging; treatment requires histologic confirmation; surgical goal is staging disease and performing complete cytoreduction to no gross residual disease. In first-line therapy, platinum-based chemotherapy is recommended; in advanced stages, patients may receive neoadjuvant chemotherapy. After neoadjuvant chemotherapy, all patients should be evaluated for interval debulking surgery. Targeted therapy is not recommended in basic or limited settings. Specialized interventions are resource-dependent, for example, laparoscopy, fertility-sparing surgery, genetic testing, and targeted therapy. Multidisciplinary cancer care and palliative care should be offered.Additional information can be found at www.asco.org/resource-stratified-guidelines. It is ASCO's view that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
Identifiants
pubmed: 34185571
doi: 10.1200/GO.21.00085
pmc: PMC8457806
doi:
Substances chimiques
CA-125 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1032-1066Références
J Glob Oncol. 2018 Jul;4:1-8
pubmed: 30110223
JAMA. 1983 Dec 9;250(22):3072-6
pubmed: 6358558
Am J Prev Med. 2016 Mar;50(3):384-394
pubmed: 26541098
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
N Engl J Med. 2019 Feb 28;380(9):822-832
pubmed: 30811909
Ann Oncol. 2016 Nov;27(11):2017-2025
pubmed: 27597548
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2015 Nov 1;33(31):3660-7
pubmed: 26324357
Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:123-139
pubmed: 28457647
Int J Gynecol Pathol. 2016 Jan;35(1):48-55
pubmed: 26166714
Am J Obstet Gynecol. 2012 Mar;206(3):242.e1-5
pubmed: 22055337
J Glob Oncol. 2018 Jul;4:1-24
pubmed: 30085844
J Clin Oncol. 2020 Apr 10;38(11):1222-1245
pubmed: 31986064
Gynecol Oncol Rep. 2018 Jun 09;25:65-69
pubmed: 29928684
J Clin Oncol. 2017 Nov 1;35(31):3618-3632
pubmed: 28892432
J Am Med Inform Assoc. 2012 Jan-Feb;19(1):94-101
pubmed: 21846779
J Clin Oncol. 2017 Jan;35(1):96-112
pubmed: 28034065
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
Gynecol Oncol. 2013 Apr;129(1):258-64
pubmed: 23266352
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Int J Clin Oncol. 2016 Jun;21(3):435-46
pubmed: 27142770
JCO Glob Oncol. 2020 Mar;6:414-438
pubmed: 32150483
J Clin Oncol. 2017 Apr 1;35(10):1103-1111
pubmed: 28221866
Cancer. 1995 Mar 15;75(6):1327-38
pubmed: 7882283
J Clin Oncol. 2020 Oct 20;38(30):3468-3493
pubmed: 32790492
Mod Pathol. 2013 Sep;26(9):1255-63
pubmed: 23558569
Front Oncol. 2020 Oct 05;10:560888
pubmed: 33123471
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
Breast J. 2006 Jan-Feb;12 Suppl 1:S3-15
pubmed: 16430397
J Clin Oncol. 2012 Sep 1;30(25):3136-40
pubmed: 22778311
Gynecol Oncol. 2016 Oct;143(1):3-15
pubmed: 27650684
J Clin Oncol. 2016 Oct 1;34(28):3460-73
pubmed: 27502591